Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06381323
Other study ID # PA2024
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date March 1, 2024
Est. completion date April 1, 2027

Study information

Verified date March 2024
Source The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Contact Ping Li, Ph.D
Phone 86-025-83106666
Email li78321@yeah.net
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of our research is to clarify the therapeutic efficacy and safety of Finerenone in patients with Primary Aldosteronism and explore the effective clinical predictive indicators of Finerenone in the treatment of Primary Aldosteronism.


Description:

Primary aldosteronism(PA) is a clinical syndrome characterized by autonomous aldosterone secretion in the body caused by adrenal cortical adenoma or hyperplasia not regulated by renin, angiotensin II, and sodium status regulation. It is the most common cause of secondary hypertension, accounting for about 10% of all hypertensive patients. The latest prospective study in China showed that the prevalence of primary aldosteronism in newly diagnosed hypertensive patients was 4%, with an additional 3% of suspicious primary aldosteronism patients. Excessive activation of the mineralocorticoid receptor (MR) in the body leads to well-known increased circulating volume overload, hypertension, and hypokalemia, as well as significantly increased cardiovascular, renal, and mortality risks. Therefore, primary aldosteronism is currently considered a new public health problem and has important implications for early diagnosis and precise treatment of primary aldosteronism. Only about 30% of patients with PA (aldosterone-producing adenoma or unilateral adrenal hyperplasia) can be cured or relieved through surgical resection, while about 65% of patients with primary aldosteronism caused by bilateral adrenal cortical hyperplasia require drug treatment. Currently, the only available drug in China is the first-generation mineralocorticoid receptor antagonist, spironolactone, which is greatly limited in its use due to its significant side effects on the gonads caused by the blockade of androgens and progesterones. Another MRA, eplerenone, which has not yet been marketed in China, is expensive and clinically inferior to spironolactone. Therefore, a large number of patients with primary aldosteronism are currently not using or using low doses of spironolactone, unable to fully counteract the high aldosterone effect, and unable to effectively control the risk of cardiovascular and renal damage. Therefore, it is necessary to explore new drugs for the treatment of primary aldosteronism. Finerenone is a newly developed novel non-steroidal MRA, which has higher affinity and selectivity for MR binding compared to steroidal MRA (spironolactone or eplerenone). Existing clinical research results suggest that Finerenone can effectively reduce the risk of cardiovascular and renal damage in patients with chronic kidney disease and diabetes, and has good safety. This study aims to be the first internationally to conduct clinical research on the use of the novel mineralocorticoid receptor antagonist finerenone for the treatment of primary aldosteronism. Through a multicenter, prospective, open-label study, the clinical efficacy and safety of this medication will be clearly established, providing high-level evidence of the use of finerenone in patients with primary aldosteronism. The project's results will offer a new option for the pharmacological treatment of primary aldosteronism, with the goal of better controlling patients' biochemical abnormalities, effectively reducing the risk of cardiovascular and renal damage, and improving disease prognosis.


Recruitment information / eligibility

Status Recruiting
Enrollment 55
Est. completion date April 1, 2027
Est. primary completion date March 1, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age:18-75 years old. 2. History of hypertension, with a sitting SBP =140 and <180 mmHg, and a sitting DBP =90 and <120 mmHg during the last two evaluations within the observation period. 3. Patients with PA who are eligible for drug treatment. 4. Diagnostic criteria for primary aldosteronism: (1) Hypertension or use of antihypertensive medications, with or without hypokalemia; (2) Screening test: Baseline plasma aldosterone to renin ratio (ARR) >30 (ng/dl)/(ng/ml/h) or ARR >2.4 (ng/dl)/(mU/L), with plasma aldosterone >15 ng/dl and plasma renin activity <1.0 ng/ml/h; (3) At least one confirmed test is positive: ? After a captopril test, plasma aldosterone decreases by <30% or plasma aldosterone is =11 ng/dl, with suppressed renin activity; ? Sitting saline infusion test results in a plasma aldosterone =10 ng/dl. 5. eGFR =60 ml/ (min*1.73m2). 6. Signed informed consent form. Exclusion Criteria: 1. Other secondary hypertension (such as renal vascular hypertension, Cushing's syndrome, subclinical Cushing's syndrome, and pheochromocytoma) or hypertensive crisis. 2. Orthostatic hypotension. 3. Heart failure, acute myocardial infarction, stroke, transient ischemic attack, or other acute cardiovascular events within the past 6 months. 4. History of adrenal surgery within the past 6 months. 5. History of carotid artery surgery within the past 6 months. 6. History of arterial vascular reconstruction surgery within the past 6 months. 7. Hospitalization within the past year due to severe hyperkalemia, with serum potassium levels <2.5 or =5.0 mmol/L. 8. Abnormal liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 2.5× upper limit of normal (ULN), total bilirubin (TBIL) > 1.5× ULN. 9. Use of spironolactone, hydralazine, or minoxidil within 30 days prior to enrollment. 10. Concurrent use of potent CYP3A4 inhibitors or inducers for treatment. 11. Known or suspected tumors; other autoimmune diseases, uncontrolled infectious diseases, severe respiratory, blood, and neurological diseases. 12. Pregnancy or planning pregnancy within 3 months before or after treatment, and breastfeeding women. 13. Mental illness, alcohol or drug abuse, inability to cooperate with treatment. 14. Patients with pacemakers. 15. Participation in other clinical trials.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Finerenone
All eligible subjects enter a 2-week enrollment phase and only take stable doses of controlled-release nifedipine. After completing baseline examinations, subjects with SBP <180 and =140 mmHg and DBP <120 and =90 mmHg enter the follow-up phase of the treatment period. Eligible subjects receive a starting dose of 20 mg qd of Finerenone. If the blood pressure is still =140/90 mmHg at week 4, serum potassium is <5.0 mmol/L, and eGFR has decreased <30% compared to baseline, the Finerenone dose is adjusted to 40 mg qd.

Locations

Country Name City State
China Department of Endocrinology, Drum Tower Hospital affiliated to Nanjing University Medical School Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Incidence of Treatment-Adverse Events as assessed by gynaecomastia, mastodynia, menstrual abnormalities, impotence, hyperkalemia and other adverse events. Adverse effects such as gynaecomastia, mastodynia, menstrual abnormalities and impotence due to its agonist activity.
Hyperkalemia.
Other adverse events.
Baseline,4 weeks,8 weeks,12 weeks,16 weeks
Primary 24h systolic BP drop value The average daytime systolic blood pressure drop from baseline levels after treatment with Finerenone at 12 weeks. 12 weeks
Secondary The change of diastolic BP from the baseline level after Finerenone treatment To Clarify the antihypertensive effect of Finerenone by measuring daytime diastolic blood pressure from baseline to the end of treatment . Baseline,4 weeks,8 weeks,12 weeks,16 weeks
Secondary Hypertension remission rate The proportion of patients with SBP<140mmHg and DBP<90mmHg. Baseline,4 weeks,8 weeks,12 weeks,16 weeks
Secondary Change of serum potassium level Proportion of patients with normal blood potassium levels (serum potassium level = 3.5mmol/L and = 5.5mmol/L). Baseline,4 weeks,8 weeks,12 weeks,16 weeks
Secondary Change of plasma renin activity to compare plasma renin activity during the progression Baseline,4 week,8 weeks,12 weeks,16 weeks
Secondary Change of ARR To see if Finerenone can influence ARR[(ng/dl)/(ng/ml/h)] Baseline,4 weeks,8 weeks,12 weeks,16 weeks
Secondary Change of UACR Compared to the placebo group, the risk of kidney disease progression in patients with type 2 diabetes and chronic kidney disease decreased by 18% after treatment with nonnarcotic ketones. Baseline,4 weeks,8 weeks,12 weeks,16 weeks
Secondary Change of eGFR Estimated glomerular filtration rate (eGFR) decline condition. Baseline,4 weeks,8 weeks,12 weeks,16 weeks
See also
  Status Clinical Trial Phase
Completed NCT02885662 - Study of CS-3150 in Patients With Primary Aldosteronism N/A
Withdrawn NCT02096939 - Microvascular Function in Primary Aldosteronism N/A
Completed NCT01728493 - Primary Aldosteronism in General Practice: Organ Damage, Epidemiology and Treatment N/A
Recruiting NCT06228677 - Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
Recruiting NCT06047912 - Screening for Primary Aldosteronism in Hypertension With 24-hour URinary aLdosterone
Recruiting NCT04991961 - Effect of Anti-hypertensive Medications on the Diagnostic Accuracy in Screening for Primary Aldosteronism
Recruiting NCT05405101 - Randomised Trial Comparing Thermal Ablation With Adrenalectomy in the Treatment of Unilateral Asymmetric PA N/A
Recruiting NCT05501080 - The Effect of SAAE on Ventricular Remodeling in PA Patients N/A
Recruiting NCT05973604 - Prevalence of Primary Aldosteronism in Atrial Fibrillation
Recruiting NCT05826080 - Effect of Adrenocorticotropic Hormone Stimulation During Adrenal Vein Sampling in Primary Aldosteronism
Completed NCT04179019 - Calcium Channel Blockade in Primary Aldosteronism Phase 2
Completed NCT03500120 - Diagnostic Accuracy of Seated Saline Suppression Test for Primary Aldosteronism
Recruiting NCT04213963 - Prospective Study on Primary Aldosteronism in Resistant Hypertension
Completed NCT05435703 - Renal Cysts and Primary Aldosteronism
Recruiting NCT02945904 - IS Metomidate PET-CT Superior to Adrenal Venous Sampling in Predicting Outcome From Adrenalectomy in Patients With Primary Hyperaldosteronism
Enrolling by invitation NCT02257450 - Primary Aldosteronism in Malaysia: A Nationwide Multicentre Study N/A
Recruiting NCT05561361 - The Effect of SAAE on Vascular Endothelial Function in PA Patients
Completed NCT03398785 - Adrenal Artery Ablation Treats Primary Aldosteronism Phase 3
Recruiting NCT04428827 - Outcome of Patients With Primary Aldosteronism
Recruiting NCT03224312 - Chongqing Primary Aldosteronism Study